Advertisement
RayBiotech
RayBiotech

Overhauling Industry-Sponsored Studies

Major pharmaceutical companies have agreed to a handful of recommendations aimed at increasing the transparency of clinical trials they fund.

By | May 23, 2012

image: Overhauling Industry-Sponsored Studies Wikimedia Commons, Adam from UK

WIKIMEDIA COMMONS, ADAM FROM UK

All clinical trial findings—even negative ones—will be made public, author contributions to manuscripts will be made clear, and study authors will have full access to all trial data in industry-funded clinical trials if a list of recommendations hashed out by editors at top medical journals and eight major pharmaceutical companies are actually implemented.

A team of 11 authors from the worlds of Big Pharma and biomedical publishing listed 10 such recommendations in a recent article that ran in the current issue of Mayo Clinic Proceedings. The recommendations arose from the Medical Publishing Insights and Practices Initiative, launched in 2008, which includes input from representatives at Merck, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Pfizer, and Takeda, as well as editors from 65 biomedical journals, among them The Lancet and the Journal of Clinical Oncology, and other members of the International Society for Medical Publication Professionals.

The eight pharmaceutical companies all affirmed their commitment to the recommendations, such as ensuring that clinical studies and publications address clinically important questions, improving understanding and disclosure of authors’ potential conflicts of interest, educating authors on how to develop quality manuscripts and meet journal expectations, reporting adverse event data more transparently and in a more clinically meaningful manner, and transparently reporting statistical methods used in analyses, among others.

But the proof of Big Pharma's commitment to these principles will, as always, be in the pudding. "The [recommendations] all seem fine,” Jerome Kassirer, former editor-in-chief of The New England Journal of Medicine told American Medical News. "The question is whether the pharmaceutical companies will practice what they preach. They don’t always do this, as is evident from the multiple multimillion-dollar suits we hear about, year after year."

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Comments

June 2, 2012

It is also absolutely essential for all Pharma sponsored studies to present the results in an understandable manner to anyone, especially the much despised "non-scientist grade medical people". The presentation statistics in any peer reviewed journal must include Number needed to treat to achieve the desired benefit and the number needed to harm.  This information is often hidden inside tortured data. I am surprised at the number of reviewers who let this pass.  

Follow The Scientist

icon-facebook icon-linkedin icon-twitter icon-vimeo icon-youtube
Advertisement

Stay Connected with The Scientist

  • icon-facebook The Scientist Magazine
  • icon-facebook The Scientist Careers
  • icon-facebook Neuroscience Research Techniques
  • icon-facebook Genetic Research Techniques
  • icon-facebook Cell Culture Techniques
  • icon-facebook Microbiology and Immunology
  • icon-facebook Cancer Research and Technology
  • icon-facebook Stem Cell and Regenerative Science
Advertisement
Horizon Discovery
Horizon Discovery
Advertisement
The Scientist
The Scientist
Life Technologies